Remix Therapeutics said it received positive preliminary results for the ongoing Phase 1 of its lead drug, REM-422, in ...

Biogen will pay a Chicago biotech $70 million upfront, plus up to $990 million in milestone payments, for an early-stage ...

A lector, a once-high-flying Bay Area biotech company that researches treatments for degenerative brain disorders like ...

BIB ETF is best suited for high-risk, active investors in the accumulation phase or retirees managing portfolios hands-on.

Join us as we dissect Summit Therapeutics' potential in the biotech sector. Can their promising drug Ansuvimab overcome the ...

The biomedical research facility in South Jersey is expected to create about 150 new permanent jobs plus 100 construction ...

Biogen specializes in therapies for complex neurological and neurodegenerative conditions. With a diversified product suite ...

In the past week or so, a gold and silver miner, a struggling offshore driller, and a biotech saw some huge insider buying.

Swiss investment company BB Biotech reported an outstanding third quarter in 2025. Here’s why.

Ipsen is acquiring next-gen immuno-oncology biotech ImCheck Therapeutics for its investigational cancer combination therapy ...

Ajooni Biotech Limited ( ($IN:AJOONI) ) has shared an announcement. Ajooni Biotech Limited has announced the successful trial run of its new ...

After years on the sidelines while investors piled into the next big thing in AI or crypto, biotech is back in focus.